YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H (HK:1558) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. has entered a licensing agreement with Shenyang Sunshine Pharmaceutical Co., Ltd. to commercialize Clifutinib Besylate in China. The agreement involves an upfront payment of RMB 60 million, with additional milestone payments contingent on certain achievements. This strategic move aims to leverage Clifutinib’s potential in the Chinese market, while the company retains rights outside of China.
For further insights into HK:1558 stock, check out TipRanks’ Stock Analysis page.